Whitehawk Therapeutics Takes Flight: A Bold New Era in Oncology Innovation

Whitehawk Therapeutics, formerly Aadi Bioscience, has unveiled a bold new identity, reinforcing its mission to revolutionize cancer treatment. With a name that embodies strength and agility, the company is doubling down on its commitment to developing next-generation antibody-drug conjugates (ADCs). Whitehawk’s portfolio, in-licensed from WuXi Biologics, utilizes cutting-edge technology to target aggressive cancers like lung and ovarian with greater precision and fewer side effects. The company's stock will trade under the ticker "WHWK" starting March 19, 2025, signaling a fresh chapter in its journey.

CEO David Lennon emphasized the company’s drive to rapidly advance its ADC pipeline, aiming to bring all three assets to investigational new drug (IND) applications within 15 months. Backed by a strong financial position, Whitehawk is set to challenge the limitations of first-generation ADCs, blending established tumor biology with breakthrough innovation. With speed, precision, and science at its core, Whitehawk is on a mission to redefine the future of cancer treatment.